Kirk Szafranski
Director HEOR, EVERSANA Value & Evidence
Expertise:
Kirk Szafranski is a Director, HEOR in the Value & Evidence Division at EVERSANA.
Kirk Szafranski holds an M.Sc. in Laboratory Medicine and Pathobiology from the University of Toronto and has extensive experience with scientific research, data analysis and scientific communications. He has worked in a wide range of therapeutic areas including cardiovascular imaging, hemophilia, oncology, neurodegenerative disease, diabetes, schizophrenia and orphan diseases such as graft-versus-host disease. At EVERSANA, Kirk has written global value dossiers, developed cost-effectiveness models, prepared budget impact analyses, developed network meta-analyses and performed analyses on individual patient-level data.
Articles by Kirk Szafranski
HemGenix Shines in Collaborative ITC Analysis: EVERSANA and CSL Behring Propel Gene Therapy to the Forefront in Hemophilia B Treatment
CSL Behring’s gene therapy for hemophilia B, HemGenix, was evaluated in the HOPE-B Phase III trial versus a basket of conventional FIX replacement products where it was found that the gene therapy reduced the annual bleed rate (ABR) versus conventional therapy. However, this trial was not powered to detect differences in the performance of HemGenix versus individual FIX replacement products such as Alprolix or IDELVION. To answer this question, CSL Behring, clinical colleagues, and EVERSANA authors including Ashley Bonner, Kirk Szafranski, Di Wang, and Sarah Walsh collaborated on an indirect treatment comparison (ITC) to evaluate the HemGenix efficacy from the HOPE-B versus efficacy from FIX replacement therapy trials (such as […]